Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egalet Ramps Up Commercial Ahead Of Abuse-Deterrent Pain Drug Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma has relaunched two drugs for pain – Sprix and Oxaydo – supported by a 50-person sales team, laying the groundwork to eventually bring to market an abuse-deterrent, extended-release morphine product.

Advertisement

Related Content

FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel